Hormone Health Hub: Expert Insights on Testing, Balance & Better Living — hormone related cancer risk

Single nucleotide variations (SNVs) in the enzymes that metabolise estrogen can significantly alter breast cancer risk — in some cases by as much as 12-fold when multiple variants combine. In this detailed scientific overview, Jillian Harrington PhD of ZRT Laboratory explains how variations in CYP11A1, CYP19A1 (aromatase), CYP1B1, COMT and MnSOD affect the estrogen metabolism pathway, why catechol estrogens are dangerous, and how methylation testing can reveal individual vulnerability.

What do heavy metals, neurotransmitters and hormone imbalances have in common? In this detailed case study, Dr. Kate Placzek examines Loretta — a 62-year-old postmenopausal woman with breast cancer — and shows how comprehensive testing can reveal the complex biochemical picture behind a cancer diagnosis. A compelling read for anyone interested in the role of hormones and toxic exposure in breast health.

Breast cancer is not one disease — it encompasses many distinct types with different attributes, degrees of invasiveness and treatment responses. Understanding the difference between invasive and non-invasive cancers, what hormone receptor status means, and which risk factors are modifiable can help women make more informed decisions about screening, lifestyle and hormone health. This article provides a clear, evidence-based overview.